Abstract:Introduction Cardiac amyloidosis is a rare and progressive form of restrictive cardiomyopathy which is associated with a poor prognosis. Two types of amyloid proteins commonly infiltrate the heart: i) immunoglobulin light-chain (AL or primary systemic) amyloid and ii) transthyretin (ATTR) amyloid. ATTR is the predominant hereditary form of cardiac amyloidosis, characterized by abnormal deposition of insoluble misfolded transthyretin protein fibrils in the myocardium resulting in organ dysfunction. The actual prevalence of ATTR amyloidosis is unknown, although recent data suggest that it is overlooked as a cause of common cardiovascular disease (CVD) especially in older people, including patients with heart failure with preserved ejection fraction (HFpEF), low-flow aortic stenosis, and atrial fibrillation. Objectives to identify patients with high-risk features for cardiac amyloidosis and assess for screening of transthyretin amyloidosis cardiomyopathy (ATTR-CM) among these patients at a safety net hospital Atlanta, GA. Methods We performed a systematic chart review of patients who had an echocardiogram between January 2018 and December 2021 at our institution. Adults aged 18 years or older with a diagnosis of cardiomyopathy or heart failure, and a left ventricular posterior wall (LVPWd) or interventricular septal wall (IVSd) thickness in diastole greater than or equal to 1.4 cm on echocardiogram were included. Patients with diagnosed AL amyloidosis and those with aortic stenosis were excluded. Variables collected included LVPWd, IVSd, gender, race, data on diagnostic modalities such as cardiac MRI (CMR), technetium pyrophosphate 99mTc scintigraphy (PYP scan), endomyocardial biopsy (EMB), and a diagnosis of cardiac amyloidosis. Results A total of 594 patients met the inclusion criteria. Of those, 215 (36.1%) were females, and 379 (63.9%) were males. Race analysis showed 91.6% were African American, 5% White, 2.1% Other and 1.1% Asian. Of the 594 included patients, only 16 (2.7%) had CMR, 68 (11.4%) had PYP scan, and 2 (0.33%) had EMB. 10 patients (1.7%) were positive for ATTR (8 of these diagnosed by PYP scan, and 2 by EMB). Discussion Less than 15% of the patients with high risk features for ATTR-CM at our institution had additional screening for this disease. These results demonstrate underutilization of imaging modalities, specifically PYP scan and CMR for the diagnosis of cardiac amyloidosis for at-risk patients at our institution. ATTR-CM is a re-emerging clinical entity that will require a high index of clinical suspicion in routine cardiac care for early diagnosis. Another project is underway focused on assessing healthcare provider and patient gaps in knowledge on the clinical features of ATTR-CM, as well as diagnosis and management of patients with cardiac amyloidosis.

Evaluating the performance and potential bias of predictive models for the detection of transthyretin cardiac amyloidosis

Detection of ATTR cardiac amyloidosis using a novel artificial intelligence algorithm for wearable-adapted noisy single-lead electrocardiograms

Tracking the pre-clinical progression of transthyretin amyloid cardiomyopathy using artificial intelligence-enabled electrocardiography and echocardiography

Artificial Intelligence Applied to Electrocardiographic Images for Scalable Screening of Transthyretin Amyloid Cardiomyopathy

Artificial intelligence to assist the echocardiographic identification of transthyretin cardiac amyloidosis

Impact of Case and Control Selection on Training Artificial Intelligence Screening of Cardiac Amyloidosis

Characterizing the progression of subclinical cardiac amyloidosis through artificial intelligence applied to electrocardiographic images and echocardiograms

Race, Sex, and Ejection Fraction-Based Differences in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Risk Prediction

Race, Sex, and Age Disparities in the Performance of ECG Deep Learning Models Predicting Heart Failure

Assessing and Mitigating Bias in Medical Artificial Intelligence

International Validation of Echocardiographic AI Amyloid Detection Algorithm

Real-world performance, long-term efficacy, and absence of bias in the artificial intelligence enhanced electrocardiogram to detect left ventricular systolic dysfunction

Validation Of The Transthyretin Amyloidosis Cardiomyopathy Score In A Black And Hispanic Screening Population: An Interim Analysis Of The First 342 Cases From The Scan-mp Study

A machine learning approach for unbiased diagnosis of acute coronary syndrome in the emergency department

Assessing Screening For Transthyretin Cardiac Amyloidosis Among Patients At A Safety Net Hospital In Metro Atlanta

Interpretable artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis

Artificial intelligence-guided detection of under-recognized cardiomyopathies on point-of-care cardiac ultrasound: a multi-center study

Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis

A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy

Detection and risk stratification of cardiac amyloidosis patients by integration of imaging and non-imaging data using a machine learning approach

Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study